The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 05, 1999

Filed:

Nov. 27, 1995
Applicant:
Inventor:

Theoharis C Theoharides, Brookline, MA (US);

Assignee:

KOS Pharmaceuticals, Inc., Miami, FL (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K / ; A61K / ;
U.S. Cl.
CPC ...
4241301 ; 4241391 ; 4241581 ; 514 12 ; 514 13 ; 514 14 ; 514 15 ; 514 16 ; 514 17 ; 514 18 ; 514 19 ; 53038824 ; 5303892 ;
Abstract

Non-traumatic immobilization (restrain) stress causes rapid degranulation of rat dura mast cells, as shown both by light and electron microscopy. These morphologic findings were accompanied by elevation of rat mast cell protease cerebrospinal fluid. Mast cell activation due to stress was abolished in animals that had been treated neonatally with capsaicin, indicating that neuropeptides in sensory nerve endings are involved in this response. Complete inhibition was also achieved by pretreating the animals intraperitoneally with antiserum to corticotropin releasing hormone (CRH). Mast cells in the dura were localized close to nerve processes containing substance P, but no CRH-fibers were identified even though these were found close to mast cells elsewhere in the brain, i.e., in the median eminence. This is the first time that stress is shown to activate intracranial mast cells, apparently through the sequential actions of CRH and one or more sensory neuropeptides such as Substance P. These findings suggest that therapy of neuroinflammatory disorders such as stress-induced migraine headaches, can be achieved with blockers of the physiological actions of CRH or inhibitors of CRH production or secretion.


Find Patent Forward Citations

Loading…